Semaglutide use for decreasing psoriasis vulgaris resource utilization: A retrospective cohort study utilizing trinetx

Summary: Abstract Body: We investigated the impact of semaglutide usage in patients with psoriasis vulgaris (PV) on resource utilization. A retrospective cohort study was performed utilizing the global database TriNetX. Patients with PV were divided based on exposure to semaglutide after their PV diagnosis. This cohort was then matched to a subset of a non-treated cohort prior to the analysis to help ensure the patients compared were of similar demographic makeup. Our primary outcome was a change in the usage of TNF-α inhibitors, calcineurin inhibitors, vitamin-D analogs, IL-17 inhibitors, IL-12/23 and IL-23 inhibitors, traditional systemic therapies, steroids, and the number of emergency room (ER) visits. Risk ratios (RR) were calculated with their associated confidence intervals (CI) to represent the change in usage. After matching, the cohort had 3,242 patients. The results demonstrated that PV patients on semaglutide had a statistically significant decreased use of nearly all measured variables, including TNF-α inhibitors, calcineurin inhibitors, vitamin-D analogs, IL-17 inhibitors, traditional systemic therapies, steroids, and the number of ER visits (RR < 1, CI did not include 1). No significant statistical difference was observed for IL-12/23 and IL-23 inhibitors (RR < 1, CI did include 1). These results are significant and may be suggestive for the use of semaglutide in patients with PV as decreased resource utilization could be indicative of fewer needs and may correlate with a decrease in PV severity. Recognizing the correlation between weight loss and PV, coupled with the growing popularity of weight loss medications, it is crucial to evaluate the effects of these medications on patients with PV. Marc A. Hill¹, Jeremy S. Bordeaux^{2, 3} 1. Case Western Reserve University School of Medicine, Cleveland, OH, United States. 2. Dermatology, University Hospitals, Cleveland, OH, United States. 3. Case Comprehensive Cancer Center, Cleveland, OH, United States. Clinical Research: Epidemiology and Observational Research